Shopping Cart
Remove All
Your shopping cart is currently empty
Motapizone (NAT 05-239) is a selective PDE3 inhibitor that suppresses cytokine release in LPS-induced human alveolar macrophages, increases intracellular cAMP, and inhibits human platelet aggregation.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $499 | Inquiry | Inquiry |
| Description | Motapizone (NAT 05-239) is a selective PDE3 inhibitor that suppresses cytokine release in LPS-induced human alveolar macrophages, increases intracellular cAMP, and inhibits human platelet aggregation. |
| In vitro | When administered at a concentration of 10 μM 15 minutes before oxidant treatment, Motapizone showed a 20% reduction in LPS-induced cytokine release from alveolar macrophages under oxidative stress conditions. Importantly, oxidative stress did not significantly affect this inhibitory effect [1]. |
| Synonyms | NAT05-239, NAT 05-239, NAT 05239 |
| Molecular Weight | 260.32 |
| Formula | C12H12N4OS |
| Cas No. | 90697-57-7 |
| Smiles | O=C1NN=C(C=2SC=C(C2)N3C=NC=C3)C(C)C1 |
| Color | Red |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||
| Solubility Information | DMSO: 1.8 mg/mL (6.91 mM), Sonication is recommended. | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
| ||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.